$599

Merck Q4 ’16 Earnings Update

Merck hosted their Q4 and full-year 2016 earnings update today. Overall, there was minimal diabetes-related discussion as the primary focus was on Keytruda.

This content is for Read Less members only.
Register
Already a member? Log in here